Leukapheresis Market worth USD 138.7 million by 2031
The report "Leukapheresis Market by Type (Filter, Membrane Separator, Centrifugal Device), Leukopak (Mobilized, Isolated PBMC), Application (Research [Cell & Gene Therapy, Transplantation], Therapeutic), Indication, End User, Region - Global Forecast to 2031" is estimated to be worth USD 90.6 million in 2026 and is poised to reach USD 138.7 million by 2031, growing at a CAGR of 8.9%.
Browse 450 market data Tables and 200 Figures spread through 500 Pages and in-depth TOC on "Leukapheresis Market, by Type (Filter, Membrane Separator, Centrifugal Device), Leukopak (Mobilized, Isolated PBMC), Application (Research [Cell & Gene Therapy, Transplantation], Therapeutic), Indication, End User, Region - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/leukapheresis-market-20283148.html
The leukapheresis market is experiencing a gradual rise fueled by the increasing occurrence of hematologic disorders and the growing usage of apheresis procedures as a standard part of clinical care. One of the important trends impacting the market is the transition from conventional hospital-based procedures to outpatient facilities and specialized apheresis centers, which opens up access, increases efficiency, and boosts procedural capacity. The participation of major healthcare systems in international clinical research is continuously growing, and the governments and research institutions’ investment in gene and cellular therapy programs are other factors that further support the market’s expansion.
Regulatory frameworks in major regions are progressively focusing on sterility, safety, and process standardization, thereby facilitating the use of single-use, closed-system disposables and consequently driving the steady demand for leukapheresis consumables.
By type, the disposables segment accounted for the largest share in the leukapheresis market in 2025.
At a global scale, the disposables segment represented the largest share of the leukapheresis market in 2025. This was mainly because of the growing focus on standardized procedures, sterilization assurance, and comprehensive traceability in healthcare systems, which have all led to an increased requirement for disposables. Disposables play an indispensable role in cell and gene therapy, related collection workflows, where process consistency, contamination control, and sample documentation are critical. CGT manufacturing is on the rise globally, with various programs, such as CAR-T, TCR-T, and stem cell, being implemented. Hence, the demand for single-use kits, tubing sets, collection bags, filters, and closed-system consumables keeps increasing.
By end user, the academic & research Institutes segment is projected to register the highest CAGR during the forecast period in this market.
The academic & research Institutes segment will likely see the fastest growth in the leukapheresis market as the development of cell and gene therapies, immuno-oncology, and stem cell biology continues. Universities, research hospitals, and public laboratories are increasingly involved in early-phase CGT development, preclinical studies, and translational research programs, all of which require high-quality leukapheresis-derived cells. Ample government funding, partnerships with biotech companies, and participation in international clinical trial networks are other factors that increase this demand. As these entities are central to innovation and early discovery, their use of leukapheresis to obtain experimental cells, optimize protocols, and source donor cells will remain strong growth drivers for this segment.
By Region, North America accounted for the largest market share in 2025.
North America led the global leukapheresis market in 2025 with a large share, mainly because of its well-developed cell and gene therapy ecosystem and high clinical adoption of leukapheresis as a primary step in CAR-T, TCR-T, NK-cell, and stem cell-based treatments. The region has a large number of accredited apheresis centers, state, of, the, art oncology hospitals, and specialized CGT manufacturing facilities spread over the US and Canada. Certain main infrastructure features like FACT, accredited transplant programs, FDA, authorized CAR-T treatment centers, and large-scale CDMO capabilities are significant factors for the continuous demand for leukapheresis. Besides, strong NIH funding, active enrollment in early- and late-stage clinical trials, and substantial funding from the biotech sector are the reasons that ensure North America’s position as the leading player in the global market.
The major players in the leukapheresis market include Terumo BCT (Japan), Fresenius Kabi (Germany), Haemonetics Corporation (US), Grifols S.A. (Spain), Macopharma (France), Medica S.p.A. (Italy), Miltenyi Biotec (Germany), Baxter International Inc. (US), Nikkiso Co., Ltd. (Japan), Immune Therapy Holdings AB (Sweden), SCTbio (Czech Republic), Biohope Scientific SL (Spain), and Caltag Medsystems Ltd. (UK). The major players in the leukopaks market include Grifols (US), Charles River Laboratories (US), STEMCELL Technologies (Canada), Lonza (Switzerland), and BioIVT (US), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Leukapheresis Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
